#USA #Boston #Morphic Medical #RESET Therapy #Terri Cooper

Morphic Medical Strengthens Its Board with New Appointment

Morphic Medical, an innovative leader in medical technology, has elevated its presence in the healthcare sector by appointing Dr. Terri Cooper to its board of directors. This appointment comes at a pivotal moment as the company is making strides with its groundbreaking device aimed at addressing the core issues related to type 2 diabetes.

Dr. Cooper brings a wealth of experience, having spent over 35 years in the biosciences and healthcare industries, where she has honed her expertise globally across various sectors. Formerly heading the U.S. Health Care Consulting practice at Deloitte, Dr. Cooper has made significant contributions to the healthcare industry by navigating complex business and regulatory landscapes. Her tenure at Deloitte was marked by initiatives that promoted innovation and propelled growth, firmly establishing her as an authority in the field.

In her new role, Dr. Cooper expressed enthusiasm about joining Morphic Medical at such a critical time for metabolic health. “I am honored to join the board of Morphic Medical,” she stated. “The company's commitment to advancing less invasive, patient-centered solutions is exactly the type of innovation our healthcare system needs today. I look forward to helping the team enhance access and improve outcomes for patients suffering from obesity and type 2 diabetes.”

Morphic Medical has been recognized for its development of RESET, a novel, incision-free endoscopic therapy designed to provide a non-surgical alternative treatment for severe obesity with comorbid cardiometabolic risks such as type 2 diabetes. The RESET therapy is not currently available for sale in the U.S. and has been designated for research purposes only, yet its potential is significant for transforming patient care.

Mike Gutteridge, President and CEO of Morphic Medical, shared his excitement regarding Dr. Cooper's appointment. “We are thrilled to welcome Dr. Terri Cooper to the board of Morphic Medical,” he remarked. “Her global leadership experience in the biosciences and healthcare sectors, along with her comprehensive insights into strategy, regulation, and organizational transformation, will be invaluable as we advance our clinical study, STEP-1, in the U.S. and establish a robust clinical and commercial foundation for our RESET therapy.”

With her extensive background in research and development in the biosciences, Dr. Cooper aims to spearhead initiatives that will further improve functionality and accessibility of RESET therapy, fostering innovation in patient-centered care. Her knowledge aligns with Morphic Medical’s mission to deliver cutting-edge solutions that stand to redefine how metabolic conditions are managed.

Founded in 2003 and headquartered in Boston, Massachusetts, Morphic Medical is at the forefront of medical innovation, creating technologies that not only respond to existing health issues but also anticipate future healthcare needs. As the company continues to expand its efforts and projects within metabolic health, Dr. Cooper’s leadership is expected to offer fresh insights and strategies that push the boundaries of current healthcare paradigms, improving life quality for countless patients.

For more information about Morphic Medical and its revolutionary RESET therapy, visit morphicmedical.com or follow them on Twitter and LinkedIn.